Vanderbilt-Ingram Cancer Center Archive — Page 19 of 27
-
October 28, 2021
VICC’s Mayer departing to take new role with AstraZeneca
Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca. -
October 21, 2021
Study evaluates how environment impacts cancer risk
Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states. -
October 14, 2021
Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer
Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer. -
September 30, 2021
Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription
Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA. -
September 23, 2021
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
-
September 23, 2021
Eng named co-chair of NCI clinical trials steering committee
Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee. -
September 16, 2021
Structural variants in breast cancer risk genes
Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.